The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
In late January 2020, in conjunction with the Ministry of Health, MSF implemented an HPV vaccination campaign for 8,500 nine-year-old girls in the Chiradzulu district of Malawi.
Fighting hepatitis C in Ukraine Millions of people in Ukraine continue to suffer silently through the pain of hepatitis C. Around five percent of the population live with the disease, many of whom remain untreated due to a historical ...
In Nsanje district, Malawi, MSF supports the severely underfunded district management team in running a fully decentralised HIV and tuberculosis (TB) programme that includes infants newly diagnosed with HIV. For 18 years, MSF has been ...
Novartis and “Drop the Case”: defending a key source of generic drugs India is sometimes called “the pharmacy of the developing world,” because it manufactures so many affordable generic medicines relied on by millions of people around ...